DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mpzp36/antibodies_in) has announced the addition of the "Antibodies in Oncology Drug Pipeline Update 2015" report to their offering.
The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies.
There are today 354 companies plus partners developing 707 antibody drugs in 1875 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 390 drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 336 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 318 out of the 320 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 56 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 26
- Pre-registration - 4
- Phase III - 54
- Phase II - 157
- Phase I - 232
- Preclinical - 471
- No Data - 10
- Suspended - 6
Ceased - 390
For more information visit http://www.researchandmarkets.com/research/mpzp36/antibodies_in